英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Barnardiston查看　Barnardiston　在百度字典中的解释百度英翻中〔查看〕
Barnardiston查看　Barnardiston　在Google字典中的解释Google英翻中〔查看〕
Barnardiston查看　Barnardiston　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
    The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
  • Evaluation of Major Cardiovascular Events in Participants . . .
    The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • In brief: Cardiovascular outcomes with bempedoic acid (Nexletol)
    In brief: Cardiovascular outcomes with bempedoic acid (Nexletol) Med Lett Drugs Ther 2023 Apr 17;65 (1674):62-63 doi: 10 58347 tml 2023 1674b
  • U. S. FDA Approves Broad New Labels for Esperion’s NEXLETOL . . .
    Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary
  • Esperion Showcases New Data from CLEAR Outcomes Highlighting . . .
    In the cardiovascular outcomes trial, the rates were 1 2% for bempedoic acid and 0 9% for placebo Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture
  • Impact of SGLT2 Inhibitors on Mortality Across Different . . .
    SGLT2 inhibitors as a class provide a consistent and significant reduction in all-cause mortality across both short-term (up to one year) and long-term follow-up, while the long-term benefit extends to chronic heart failure, CKD, and high-risk DM Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer glucose-lowering, cardio-protective and reno-protective properties Mortality rates
  • SGLT2 Inhibitors: What They Are, Uses Side Effects
    SGLT2 inhibitors also lower the risk of heart failure flare-ups How do SGLT2 inhibitors work? SGLT2 is a protein in your kidneys that reabsorbs glucose Typically, when glucose in your blood flows through your kidneys, some glucose goes back into your bloodstream These medications block that process, so your kidneys don’t reabsorb glucose
  • FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
    U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use





中文字典-英文字典  2005-2009